Trevi Therapeutics ((TRVI)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trevi Therapeutics’ recent earnings call painted an optimistic picture for the company’s future, despite reporting a net loss and increased expenses. The sentiment was buoyed by successful trial results, a robust financial position, and positive stakeholder feedback, all contributing to a forward-looking confidence in their strategic advancements and upcoming trials.
Successful CORAL Trial Results
Trevi Therapeutics announced promising outcomes from their CORAL trial, which focused on chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial met its primary endpoint, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups. Notably, the Leicester Cough Questionnaire revealed marked improvements, with increases of 3.7 and 3.4 points for the 54 and 108 mg BID doses, respectively.
Strong Financial Position
The company has fortified its financial standing by raising approximately $115 million in capital, resulting in a total cash and investments of around $204 million by the end of June 2025. This financial cushion is expected to sustain Trevi’s operations into 2029, providing a solid foundation for future endeavors.
Phase III Program Planning
Trevi is gearing up to initiate Phase III trials for chronic cough in IPF patients in the first half of next year. Additionally, the company is planning studies for non-IPF interstitial lung diseases and refractory chronic cough, marking a significant step forward in their clinical development pipeline.
Positive Stakeholder Feedback
Feedback from the patient advisory board has been overwhelmingly positive, with stakeholders indicating that the results from the CORAL trial could significantly enhance patients’ daily lives. This endorsement underscores the potential impact of Trevi’s developments on patient well-being.
Net Loss Reported
Trevi reported a net loss of $12.3 million for the second quarter of 2025, a slight improvement from the $12.4 million loss in the same quarter of the previous year. This indicates a stable financial trajectory despite the challenges faced.
Increased G&A Expenses
General and administrative expenses rose to $4.3 million in Q2 2025, up from $3.3 million in Q2 2024. This increase was primarily attributed to higher professional fees and personnel expenses, reflecting the company’s expanding operations.
Forward-Looking Guidance
Trevi Therapeutics provided a comprehensive outlook during the earnings call, emphasizing their strong financial position with cash and investments totaling approximately $204 million as of June 30, 2025. This financial strength is expected to support their operational activities into 2029, including two Phase III trials for IPF-related chronic cough, a planned trial for non-IPF interstitial lung disease cough, and their next RCC trial. Clinically, the company plans to initiate Phase III trials in the first half of 2026 and has several Phase I studies underway.
In summary, Trevi Therapeutics’ earnings call conveyed a positive sentiment, driven by successful trial results, a strong financial position, and encouraging stakeholder feedback. Despite reporting a net loss and increased expenses, the company’s strategic advancements and preparations for upcoming trials position it well for future growth and success.